Compare CBIO & STRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | STRT |
|---|---|---|
| Founded | 2003 | 1908 |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | | Auto Parts:O.E.M. |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.8M | 303.7M |
| IPO Year | N/A | 1996 |
| Metric | CBIO | STRT |
|---|---|---|
| Price | $19.39 | $79.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $26.67 | ★ $93.00 |
| AVG Volume (30 Days) | ★ 221.2K | 77.4K |
| Earning Date | 05-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.53 |
| EPS | N/A | ★ 3.26 |
| Revenue | N/A | ★ $439,195,000.00 |
| Revenue This Year | N/A | $4.22 |
| Revenue Next Year | $279.20 | $2.04 |
| P/E Ratio | ★ N/A | $24.66 |
| Revenue Growth | N/A | ★ 5.24 |
| 52 Week Low | $8.72 | $31.71 |
| 52 Week High | $20.58 | $92.50 |
| Indicator | CBIO | STRT |
|---|---|---|
| Relative Strength Index (RSI) | 71.01 | 50.14 |
| Support Level | $10.89 | $72.27 |
| Resistance Level | $20.58 | $84.29 |
| Average True Range (ATR) | 1.91 | 3.54 |
| MACD | 0.20 | 0.62 |
| Stochastic Oscillator | 89.33 | 52.88 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.